Circulating tumor cells are associated with bone metastasis of lung cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 15, 2014, Pages 6369-6374

  Cheng, Min ^a   Liu, Lin ^a   Yang, Hai Shan ^a   Liu, Gui Feng ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Bone metastasis; Circulating tumor cells; Lung cancer; MRI

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; BONE TUMOR; CANCER STAGING; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECONDARY; SMALL CELL LUNG CANCER; SQUAMOUS CELL CARCINOMA; TUMOR EMBOLISM; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; SMALL CELL LUNG CARCINOMA;

EID: 84906267805     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.15.6369     Document Type: Article

References (40)

1. Al Husaini H, Wheatley-Price P, Clemons M, Shepherd FA (2009). Prevention and management of bone metastases in lung cancer: a review. J Thorac Oncol, 4, 251-9.
2. Brown JE, Cook RJ, Major P, et al. (2005). Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst, 97, 59-69.
3. Carney DN (2002). Lung cancer-time to move on from chemotherapy. N Engl J Med, 346, 126-8.
4. Chute JP, Chen T, Feigal E, et al. (1999). Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol, 17, 1794-801.
5. Cristofanilli M (2014). Circulating tumour cells: telling the truth about metastasis. Lancet Oncol, 15, 365-6.
6. Cristofanilli M, Budd GT, Ellis MJ, et al. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med, 351, 781-91.
7. Currie GP, Kennedy AM, Denison AR (2009). Tools used in the diagnosis and staging of lung cancer: what's old and what's new? QJM, 102, 443-8.
8. Fidler IJ (1978). Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res, 38, 2651-60.
9. Goldstraw P, Crowley J, Chansky K, et al (2007). The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2, 706-14.
10. Gorges TM, Tinhofer I, Drosch M, et al (2012). Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer, 12, 178.
11. Gregory DL, Hicks RJ, Hogg A, et al (2012). Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med, 53, 1007-15.
12. Grover PK, Cummins AG, Price TJ, et al (2014). Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann Oncol, 25, 1506-16.
13. Hamilton W, Sharp D (2004). Diagnosis of lung cancer in primary care: a structured review. Fam Pract, 21, 605-11.
14. Herbst RS, Heymach JV, Lippman SM (2008). Lung cancer. N Engl J Med, 359, 1367-80.
15. Hiltermann TJ, Pore MM, van den Berg A, et al (2012). Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol, 23, 2937-42.
16. Hou JM, Krebs M, Ward T, et al (2011). Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol, 178, 989-96.
17. Isobe K, Hata Y, Kobayashi K, et al (2012). Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer. Anticancer Res, 32, 3339-44.
18. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
19. Krebs MG, Hou JM, Ward TH, et al (2010). Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol, 2, 351-65.
20. Lee JW, Lee SM, Lee HS, et al (2012). Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients with small cell lung cancer. Ann Nucl Med, 26, 627-33.
21. Ma XL, Xiao ZL, Liu L, et al (2012). Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer. Asian Pac J Cancer Prev, 13, 1137-44.
22. Mego M, De Giorgi U, Broglio K, et al (2009). Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. Br J Cancer, 101, 1813-6.
23. Mulshine JL, Smith RA (2002). Lung cancer. 2: screening and early diagnosis of lung cancer. Thorax, 57, 1071-8.
24. Ni X, Zhuo M, Su Z, et al. (2013). Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci USA, 110, 21083-8.
25. O'Flaherty JD, Gray S, Richard D, et al (2012). Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer, 76, 19-25.
26. Pierga JY, Bidard FC, Cropet C, et al (2013). Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial. Ann Oncol, 24, 2999-3004.
27. Portilla-Quattrociocchi H, Banzo I, Martinez-Rodriguez I, et al. (2011). (Evaluation of bone scintigraphy and (18) F-FDG PET/CT in bone metastases of lung cancer patients). Rev Esp Med Nucl, 30, 2-7.
28. Riethdorf S, Wikman H, Pantel K (2008). Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer, 123, 1991-2006.
29. Schmidt GP, Reiser MF, Baur-Melnyk A (2009). Wholebody MRI for the staging and follow-up of patients with metastasis. Eur J Radiol, 70, 393-400.
30. Shapley M, Mansell G, Jordan JL, Jordan KP (2010). Positive predictive values of >/=5% in primary care for cancer: systematic review. Br J Gen Pract, 60, 366-77.
31. Shiota M, Bishop JL, Nip KM, et al (2013). Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res, 73, 3109-19.
32. Sone S, Yano S (2007). Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone. Cancer Metastasis Rev, 26, 685-9.
33. Stenbygaard LE, Sorensen JB, Larsen H, Dombernowsky P (1999). Metastatic pattern in non-resectable non-small cell lung cancer. Acta Oncol, 38, 993-8.
34. Stovold R, Blackhall F, Meredith S, et al (2012). Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells. Lung Cancer-J Iaslc, 76, 263-8.
35. Tarhan MO, Gonel A, Kucukzeybek Y, et al (2013). Prognostic significance of circulating tumor cells and serum CA15-3 levels in metastatic breast cancer, single center experience, preliminary results. Asian Pac J Cancer Prev, 14, 1725-9.
36. Tseng JY, Yang CY, Liang SC, et al (2014). Interleukin-17A modulates circulating tumor cells in tumor draining vein of colorectal cancers and affects metastases. Clin Cancer Res, 20, 2885-97.
37. Turker I, Uyeturk U, Sonmez OU, et al (2013). Detection of circulating tumor cells in breast cancer patients: prognostic predictive role. Asian Pac J Cancer Prev, 14, 1601-7.
38. Wang FB, Yang XQ, Yang S, et al (2011). A higher number of circulating tumor cells (CTC) in peripheral blood indicates poor prognosis in prostate cancer patients-a meta-analysis. Asian Pac J Cancer Prev, 12, 2629-35.
39. Wang Y, van Klaveren RJ, van der Zaag-Loonen HJ, et al (2008). Effect of nodule characteristics on variability of semiautomated volume measurements in pulmonary nodules detected in a lung cancer screening program. Radiology, 248, 625-31.
40. Wong MP (2012). Circulating tumor cells as lung cancer biomarkers. J Thorac Dis, 4, 631-4.